


AMENDMENTS TO THE CLAIMS

1. (Previously presented) A *cis*-platinum complex of the formula Ia or Ib



or a pharmaceutically acceptable salt thereof

wherein:

each A is independently halo, hydroxy or carboxylate;

each B is independently halo, hydroxy, carboxylate, carbamate ester or carbonate ester;

Z of formula Ia is a substituted 5- or 6-membered heterocyclic amine selected from the group consisting of pyrazole, imidazole, oxazole and pyrazine, said heterocyclic amine having at least two alkyl substituents, wherein said alkyl substituent sterically hinders access of the Pt atom to a DNA strand of a tumor cell, and wherein all substituents on the heterocycle are alkyl substituents;


Z of formula Ib is a substituted 5- or 6-membered heterocyclic amine selected from the group consisting of pyrazole, imidazole, oxazole and pyrazine, said heterocyclic amine having at least one alkyl substituents, wherein said alkyl substituent sterically hinders access of the Pt atom to a DNA strand of a tumor cell, and wherein all substituents on the heterocycle are alkyl substituents;

and X is NH₃ or mono- or dialkyl substituted NH₃.

2. (Canceled)
3. (Original) The complex of claim 1 wherein both A are halo.
4. (Original) The complex of claim 3 wherein both A are chloro.
5. (Original) The complex of claim 1 wherein both B are hydroxy or carboxylate.

6. (Original) The complex of claim 1 wherein X is NH_3 .
7. (Original) The complex of claim 4 wherein X is NH_3 .
- 8-13. (Canceled)
14. (Currently amended) The complex of claim 1[[2]] wherein Z is 1,3,5-trimethylpyrazole.
15. (Previously presented) The complex of claim 1 wherein said at least one substituent is coupled to the heterocycle at a position other than the position adjacent to the coordinating atom in said heterocycle.
16. (Original) The complex of claim 1 wherein the solubility of the compound in aqueous solution is greater than or equal to 1 mg/ml.
17. (Previously presented) A complex selected from the group consisting of
(SP-4-3)-amminedichloro(1,2-dimethylimidazole)platinum(II);
(SP-4-3)-amminedichloro(2,5-dimethylimidazole)platinum(II);
(SP-4-3)-amminedichloro(3,5-dimethylpyrazole)platinum(II);
(SP-4-3)-amminedichloro(1,3,5-trimethylpyrazole)platinum(II);
(SP-4-3)-amminedichloro(2,3-dimethylpyrazine)platinum(II);
(SP-4-3)-amminedichloro(2,5-dimethylpyrazine)platinum(II);
(SP-4-3)-amminedichloro(2,4,5-trimethyloxazole)platinum(II);
(SP-4-3)-amminedichloro(3,5-dimethylisoxazole)platinum(II);
(OC-6-43)-amminedichlorodihydroxo(1-methylimidazole)platinum(IV);
(OC-6-43)-amminedichlorodihydroxo(1,2-dimethylimidazole)platinum(IV);
(OC-6-43)-amminedichlorodihydroxo(2,5-dimethylimidazole)platinum(IV);
(OC-6-43)-amminedichlorodihydroxo(3,5-dimethylpyrazole)platinum(IV);
(OC-6-43)-amminedichlorodiacetato(2,3-dimethylpyrazine)platinum(IV); and
(OC-6-43)-amminedichlorodihydroxo(2,3-dimethylpyrazine)platinum(IV).
18. (Original) A pharmaceutical composition comprising as active ingredient the complex of claim 1, in admixture with a pharmaceutically acceptable diluent or carrier and optionally one or more other therapeutic agents.

19. (Original) The composition of claim 18, in unit dosage form.
20. (Original) The composition of claim 18 for oral administration.
21. (Canceled)
22. (Previously presented) A *cis*-platinum complex of the formula Ia ~~[[σ -Ib]]~~



Ia

or a pharmaceutically acceptable salt thereof

wherein:

each A is independently halo, hydroxy or carboxylate;

each B is independently halo, hydroxy, carboxylate, carbamate ester or carbonate ester;

Z is a substituted 5- or 6-membered heterocyclic amine selected from the group consisting of pyrazole, imidazole, oxazole and pyrazine, said heterocyclic amine having at least one alkyl substituent coupled to the heterocycle at a position one atom removed from the coordination atom in the heterocycle and wherein all substituents on the heterocycle are alkyl substituents;

and X is NH_3 or mono- or dialkyl substituted NH_3 .

23. (Previously presented) The complex of claim 22, wherein said complex is (SP-4-3)-amminedichloro(2-methylimidazole)platinum(II).